Effectiveness and Safety of Aspirin Use for Primary Prevention of Cardiovascular Disease in Diabetic Patients
Article Sidebar
Main Article Content
Abstract
Background: Diabetes patients are at a higher risk of cardiovascular events. Aspirin is used for primary prevention but increases the risk of bleeding. The balance of benefits and hazards for the prevention of first cardiovascular events is unclear.
Objectives: To assess the effectiveness and safety of aspirin use for the primary prevention of cardiovascular disease in diabetic patients
Design: This was a retrospective cohort study.
Methods: Data were collected from diabetes patients older than or equal to 50 years of age without evidence of cardiovascular disease. The aspirin and non-aspirin groups were compared.
Results: From a total of 660 diabetes patients, 69.39% in the aspirin group were female, with a mean age of 67.8 (± 8.49) years, and LDL cholesterol level of 100.16 ( ± 37.13) mg/dl, which was not different from the aspirin group, except for HDL cholesterol levels in females. Both groups were not significantly different in risk of coronary artery disease (HR = 0.654 [95% CI 0.175-2.437]; P = 0.527) and ischemic stroke (HR = 0.833 [95% CI 0.168-4.133]; P = 0.823).
Conclusions: Diabetic patients who used aspirin for primary prevention of cardiovascular disease occurring coronary artery disease and ischemic stroke were not significantly different from those who did not. Further studies may focus on another antiplatelet drug, such as Clopidogrel.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
เนื้อหาและข้อมูลในบทความที่ลงตีพิมพ์ในวารสาร PCFM ถือเป็นข้อคิดเห็นและความรับผิดชอบของผู้เขียนบทความโดยตรง ซึ่งกองบรรณาธิการวารสารไม่จำเป็นต้องเห็นด้วยหรือร่วมรับผิดชอบใด ๆ
บทความ ข้อมูล เนื้อหา รูปภาพ ฯลฯ ที่ได้รับการตีพิมพ์ลงในวารสาร PCFM ถือเป็นลิขสิทธิ์ของวารสาร PCFM หากบุคคลหรือหน่วยงานใดต้องการนำทั้งหมดหรือส่วนหนึ่งส่วนใดไปเผยแพร่ต่อหรือเพื่อกระทำการใด ๆ จะต้องได้รับอนุญาตเป็นลายลักษณ์อักษรจากวารสาร PCFM ก่อนเท่านั้น
References
The alarming rise in diabetes around the world. International Diabetes Federation Diabetes atlas 9th edition.2019[cited 2020 July 12]. Available from: http:// https://www.idf.org/e-library/epidemiology-research/diabetes-atlas/159-idf-diabetes-atlas-ninth-edition-2019.html.
Stategy and Planning Division, Minstry of Public Health. Public Health statistics A.D.2020 [cited 2020 Aug 18]. Available from: https://spd.moph.go.th/new_bps/sites/default/files/2563_0.pdf.
Leon BM, Maddox TM. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes. 2015 Oct 10;6(13):1246–58.
Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, Del Cañizo-Gómez FJ. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes. 2014 Aug 15;5(4):444–70.
Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018 08;17(1):83.
The ASCEND Study Collaborative Group. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med. 2018 Oct 18;379(16):1529–39.
Ikeda Y, Shimada K, Teramoto T, Uchiyama S, Yamazaki T, Oikawa S, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA. 2014 Dec 17;312(23):2510–20
Saito Y, Okada S, Ogawa H, Soejima H, Sakuma M, Nakayama M, et al. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial. Circulation. 2017 Feb 14;135(7):659–70.
สมาคมโรคเบาหวานแห่งประเทศไทย ในพระราชูปถัมภ์สมเด็จพระเทพรัตนราชสุดาฯ สยามบรมราชกุมารี. แนวทางการป้องกันและรักษาภาวะแทรกซ้อนของหลอดเลือดหัวใจและหลอดเลือดสมอง. แนวทางเวชปฏิบัติสำหรับโรคเบาหวาน 2560 = clinical Practice Guideline for diabetes 2017. พิมพ์ครั้งที่ 3. ปทุมธานี: บริษัท ร่มเย็น มีเดีย จำกัด; 2560. หน้า 134.
Bibbins-Domingo K. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statement. Ann Int Med 2016; 164(12): 836-45.
The Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials. Lancet 2009; 373: 1849-60.
Mo C, Sun G, Lu ML, Zhang L, Wang YZ, Sun X, et al. Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries. World J Gastroenterol. 2015;21:5382-92.
วรรณคล เชื้อมงคล.การใช้แอสไพรินเพื่อป้องกันปฐมภูมิต่อการเกิดโรคหัวใจและหลอดเลือดในผู้ป่วยเบาหวานชนิดที่ 2 [นิพนธ์ต้นฉบับ/สาขาวิชาเภสัชกรรคลินิก คณะเภสัชศาสตร์].นครนายก: มหาวิทยาลัยศรีนครินทรวิโรฒ; 2562.
Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation. 2010 Jun 22;121(24):2694–701.
Zhang C, Sun A, Zhang P, Wu C, Zhang S, Fu M, et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. Diabetes Res Clin Pract. 2010 Feb;87(2):211–8.
Bertoluci MC, Rocha VZ. Cardiovascular risk assessment in patients with diabetes. Diabetol Metab Syndr. 2017;9:25.
Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N. Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. Arch Intern Med. 2011 Mar 14;171(5):404–10.
Okada S, Morimoto T, Ogawa H, Sakuma M, Soejima H, Nakayama M, et al. Effect of low-dose aspirin on primary prevention of cardiovascular events in Japanese diabetic patients at high risk. Circ J. 2013;77(12):3023–8.
Xie M, Shan Z, Zhang Y, Chen S, Yang W, Bao W, et al. Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status. PLoS One. 2014;9(10):e90286.
Whitlock EP, Burda BU, Williams SB, Guirguis-Blake JM, Evans CV. Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force. Ann Intern Med. 2016 Jun 21;164(12):826.